Cytokine gene modified antigen-presenting cell/tumor cell conjugate, its preparation and use
AssigneeShanghai Medipharm Biotech Co., Ltd.
InventorsJu Dianwen, Qun Tao, Dan Ye
Life of this patent
Estimating the term…
Abstract
The present invention provides an antigen-presenting cell(APC)/tumor cell conjugate, wherein the antigen-presenting cell (APC) is modified by a cytokine gene selected from the group consisting of IL-2, IL-3, IL-4, IL-6, IL-12, IL-18, IFNα, IFNβ, IFNγ, TNF, TGF, GM-CSE, and the combination thereof. The conjugate is useful as a tumor vaccine to significantly induce an immunity specifically against the tumor cell The present invention also provides the method for preparing the conjugate and a pharmaceutical composition containing said conjugate.
Claims10
An autoloaous antigen-presenting cell-autologous tumor cell conjugate, wherein the autologous antigen-presenting cell (APC) is modified by a polynucleotide encoding and expressing IL-18.
A method for preparing an autologous antigen-presenting cell/autologous tumor cell conjugate, comprising the steps of:
- (1) providing an autologous antigen-presenting cell and an autologous tumor cell, wherein the autologous antigen-presenting cell is modified by a polynucleotide encoding and expressina IL-18;
- (2) incubating the APC and the tumor cell at a ratio of 100:1–0.1:1 in a temperature range of 30–38° for 1–100 hrs to form the antigen-presenting cell/tumor cell conjugate.
Dependencies are inferred from the claim text.